PRIA Logo™
119-hr-1405119th Congress

Enhancing Domestic Drug Manufacturing Competitiveness Act

Sponsored By: Representative Buchanan, Vern [R-FL-16]

Introduced

Summary

Regulatory barriers to U.S. pharmaceutical manufacturing. This bill would require the Comptroller General of the United States to study which environmental and other regulations add time or cost to siting or expanding drug manufacturing in the U.S., compare U.S. rules with other countries, and recommend ways to speed reviews and adopt technological solutions.

Show full summary
  • Drug manufacturers would get a focused assessment of the specific time and cost hurdles that slow building or expanding domestic drug plants.
  • Regulators and policymakers would receive recommended actions, including expediting reviews, inspections, and approvals, to address identified barriers.
  • The study would examine how regulations affect pharmaceutical supply chain resiliency and offer recommendations to reduce vulnerability to shortages.
  • The Comptroller General would engage stakeholders to identify promising manufacturing technologies and the policies needed to support them and would submit a report to Congress within 1 year.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

No Economic Impacts Identified for this Bill

Sponsors & CoSponsors

Sponsor

Buchanan, Vern [R-FL-16]

FL • R

Cosponsors

  • Rep. Donalds, Byron [R-FL-19]

    FL • R

    Sponsored 2/18/2025

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation